SARS-CoV-2 and type I interferon signaling in brain endothelial cells: Blurring the lines between friend or foe

Vavougios G.D., Zarogiannis S.G., Hadjigeorgiou G., Krogfelt K.A., Gourgoulianis K.I.

Heterogeneity of Baló’s concentric sclerosis: a study of eight cases with different therapeutic concepts

Tzanetakos D., Vakrakou A.G., Tzartos J.S., Velonakis G., Evangelopoulos M.E., Anagnostouli M., Koutsis G., Dardiotis E., Karavasilis E., Toulas P., Stefanis L., Kilidireas C. (2020)

Background: Baló’s Concentric Sclerosis (BCS) is a rare heterogeneous demyelinating disease with a variety of phenotypes on Magnetic Resonance Imaging (MRI). Existing literature lacks data especially on the therapeutic ...

Thinking outside the ischemia box: Advancements in the use of multiple sclerosis drugs in ischemic stroke

Aloizou A.-M., Siokas V., Pateraki G., Liampas I., Bakirtzis C., Tsouris Z., Lazopoulos G., Calina D., Docea A.O., Tsatsakis A., Bogdanos D.P., Dardiotis E. (2021)

Ischemic stroke (IS) is a major cause of death and disability, despite early intervention. Thrombo-inflammation, the inflammatory process triggered by ischemia, is a concept that ties IS with multiple sclerosis (MS), under ...

Anti-cd20 agents for multiple sclerosis: Spotlight on ocrelizumab and ofatumumab

Florou D., Katsara M., Feehan J., Dardiotis E., Apostolopoulos V. (2020)

Until recently, in the pathogenesis of Multiple Sclerosis (MS), the contribution of B cells has been largely underestimated, and the disease was considered a T-cell-mediated disorder. However, newer evidence shows that B ...